Abstract
The beneficial role of gut microbiota and bacterial metabolites, including short-chain fatty acids (SCFAs), is well recognized; although the available literature around their role in colorectal cancer (CRC) has been inconsistent.
We performed a systematic review and meta-analysis to examine associations of fecal SCFA concentrations to the incidence and risk of CRC.
Data extraction through Medline, Embase, and Web of Science was carried out from database conception to May 21, 2021. Predefined criteria included human clinical observational studies, while excluding cell/animal model studies, conference proceedings, and reviews. Quality assessment of selected 16 case-control and six cross-sectional studies is reported using PRISMA 2020 guidelines. Studies were categorized for CRC risk or incidence, and RevMan 5.4 was used to perform the meta-analyses. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model.
Combined analysis of acetic-, propionic-, and butyric-acid revealed significantly lower concentrations of these SCFAs in individuals with high-risk of CRC (SMD = 2.02, 95% CI 0.31 to 3.74, P = 0.02). Further, CRC incidence increased in individuals with lower levels of SCFAs (SMD = 0.45, 95% CI 0.19 to 0.72, P = 0.0009), compared to healthy individuals.
Overall, lower fecal concentrations of the three major SCFAs is associated with higher risk and incidence of CRC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EA acknowledges PhD scholarship from the WSU, WKMW is supported through the Leona M. and Harry B. Helmsley Charitable Trust (Grant 2018PG-T1D009 to AAH) in collaboration with the JDRF Australian Type 1 Diabetes Clinical Research Network funding (Grant 3-SRA-2019-694-M-B to AAH). AAH is supported by grants from Juvenile Diabetes Research Foundation (JDRF) Australia T1D Clinical Research Network (JDRF/4-CDA2016-228-MB) and Visiting Professorships (2016-18 and 2019-22) from the Danish Diabetes Academy, funded by the Novo Nordisk Foundation, grant number NNF17SA0031406.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medline, Embase, and Web of Science database search was performed for articles involving human subjects that are in English from database conception until 21st May 2021. The details of the search keywords and strategies utilized in Ovid and Web of Science are available in the Supplementary Methods section.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
One of the research papers that was selected in the systematic review was recently retracted. This revision presents an updated analysis after removing the retracted article from the previous version.
Data Availability
All data produced in the present work are contained in the manuscript
